Status:
COMPLETED
Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborating Sponsors:
Tokyo Medical and Dental University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
20-80 years
Brief Summary
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may al...
Detailed Description
OBJECTIVES: * Identify the prognostic factors in patients with curatively resected stage II colon cancer receiving adjuvant chemotherapy with tegafur-uracil. * Identify predictive factors of chemosen...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the colon or rectosigmoid
- Stage II disease
- Must be registered on clinical trial TMDU-BRI-CC-05-01
- Must have resected tumor tissue available
- No hereditary colorectal cancer
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
1111 Patients enrolled
Trial Details
Trial ID
NCT00898846
Start Date
October 1 2006
End Date
September 1 2016
Last Update
September 28 2016
Active Locations (152)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagoya Ekisaikai Hospital
Nagoya, Aichi-ken, Japan, 454-8502
2
Ban Buntane Houtokukai Hospital
Nagoya, Aichi-ken, Japan, 454-8509
3
Nagoya University Hospital
Nagoya, Aichi-ken, Japan, 466-8550
4
Nagoya University School of Medicine
Nagoya, Aichi-ken, Japan, 466